Societal CDMO (FRA:RAH) Common Stock : €0.96 Mil (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Societal CDMO Common Stock?

Societal CDMO's quarterly common stock increased from Jun. 2023 (€0.83 Mil) to Sep. 2023 (€0.98 Mil) but then declined from Sep. 2023 (€0.98 Mil) to Dec. 2023 (€0.96 Mil).

Societal CDMO's annual common stock increased from Dec. 2021 (€0.41 Mil) to Dec. 2022 (€0.80 Mil) and increased from Dec. 2022 (€0.80 Mil) to Dec. 2023 (€0.96 Mil).

Societal CDMO Common Stock Historical Data

The historical data trend for Societal CDMO's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Societal CDMO Common Stock Chart

Societal CDMO Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

0.21

0.24

0.41

0.80

0.96

Societal CDMO Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Common Stock	Get a 7-Day Free Trial															0.80	0.79	0.83	0.98	0.96

Societal CDMO Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Societal CDMO (FRA:RAH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Societal CDMO Inc (FRA:RAH) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

SCTL:USA

Address

1 E. Uwchlan Avenue, Suite 112, Exton, PA, USA, 19341

Website

https://www.societalcdmo.com

Societal CDMO Inc is a bi-coastal contract development and manufacturing organization. It offers capabilities spanning pre-Investigational New Drug development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms primarily focused on small molecules. The company also provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging, and logistics services to the global pharmaceutical market.

Societal CDMO (FRA:RAH) Headlines

No Headlines